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1. Introduction
Melanoma is an extremely complicated disease, with many gene mutations and alternations
in signaling pathways. Because effective treatment for melanoma is lacking, the prognosis
for metastatic melanoma patients remains very poor. Over the past 30 years, significant ef‐
forts have been made to search for better agents or strategies to fight this deadly disease.
Numerous clinical trials at different stages have been carried out. Although most of them
have failed, some did show very promising results. New treatment strategies have resulted
in paradigm shift in our approach to melanoma therapy. These shining examples may mark‐
edly change our philosophy about melanoma treatment.
The year 2011 marked a fruitful year for melanoma research. The FDA approved three
drugs for advanced melanoma treatment: ipilimumab (an anti-cytotoxic T lymphocyte anti‐
gen-4 monoclonal antibody), vemurafenib (a selective BRAF inhibitor), and pegylated inter‐
feron-α2b for adjuvant setting usage [1]. However, there are still significant limitations for
melanoma treatment. Ipilimumab only prolonged the survival time for metastatic melano‐
ma patient from an average of 6.5 months to an average of 10 months. This treatment also
has been associated with strong immunological adverse effects; severe to fatal autoimmune
reactions were seen in 12.9% of patients treated with ipilimumab in a clinical trial that enrol‐
led 676 melanoma patients [2]. Vemurafenib is not effective for melanoma patients with
wide type BRAF, and confirmation of BRAFV600E mutation-positive melanoma using an
FDA-approved test is required before treatment with vemurafenib. This treatment also only
prolonged the median survival time for advanced melanoma patients 2~3 months [1]. More
importantly, despite the high initial response rate for patients with BRAFV600E mutation to
vemurafenib, virtually all the patients developed primary or acquired resistance to this drug
in the end [3]. With the rapidly rising incidents of this disease and the high resistance to cur‐
rent therapeutic agents, developing more effective drugs for melanoma is very important.
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In this chapter, we will review available therapeutic agents for advanced melanoma as well
as agents that are still under clinical development. We will focus on their mechanism of ac‐
tion, development history, and therapeutic effects. In learning from our efforts in the past,
we must continue to challenge the current paradigms of treatment as we forge new paths to
more effective treatment options. This will likely involve a multimodal approach to therapy
utilizing all of the available tools in our arsenal.
2. Chemotherapy agents
According to the current 7th edition American Joint Committee of Cancer (AJCC) staging
system, melanoma can be pathologically classified in the following stages: 0, IA, IB, IIA, IIB,
IIC, IIIA, IIIB, IIIC, and IV. Stage 0 is in situ melanoma. Stage I and II are growth phase of
localized cutaneous melanoma with increasing thickness. Stage III has regional involvement
of lymph node. Stage IV means distant metastasis. Normally stage III and IV melanoma are
called metastatic melanoma. Localized melanoma is curable with complete surgical excision
in most patients. But currently treatment for metastatic melanoma is still very challenging.
Only two chemotherapy drugs in current use have been approved by the Food and Drug
Administration (FDA) for metastatic melanoma: dacarbazine (DTIC) and vemurafenib. Oth‐
er agents that have been tried on melanoma patients are also discussed below.
2.1. Dacarbazine (DTIC)
DTIC is the first FDA approved chemotherapy drug for metastatic melanoma. This drug
gained FDA approval in May 1975 as DTIC-Dome for the treatment of metastatic melanoma.
It was initially marketed by Bayer. The therapeutic effect of DTIC is believed to be produced
through alkylation of DNA. While its anticancer mechanism of action is still not fully under‐
stood, DTIC is believed to be first metabolically bioactivated through a series of reactions
involving CYP450. Initial demethylation to MTIC [3-methyl-(triazen-1-yl)imidazole-4-car‐
boxamide] is followed by formation of diazomethane, the active moiety of DTIC and a po‐
tent methylating agent [4].
DTIC has produced response rates of from 15% to 25% in single-institution trials. But the
overall response rate has fallen over the years from 15% to 7% and less than 5% of responses
are complete in phase 3 trials. The median response durations to DTIC are 5 to 6 months.
Long-term follow-up of patients treated with DTIC alone shows that only <2% can be antici‐
pated to survive for more than 6 years. In recent phase 3 trials that used strict response as‐
sessment criteria, the response rates with single-agent DTIC did not exceed 12% [5].
Over the past 30 years after its approval by the FDA, DTIC remains the only currently used
cytotoxic drug for the treatment of metastatic melanoma. Despite its low single-agent activi‐
ty, DTIC has remained the mainstay of many combination chemotherapy regimens and
evaluations of resistance-reversing agents. After more than 20 years of research, DTIC is still
the standard against which most new chemotherapy agents are compared [6].
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As for the dose, it has been demonstrated that 850~1000 mg/m2 single dose of DTIC is toler‐
ated. This single dose administration appears to deliver clinical improvements similar to
those observed with multiple doses that provide the same total dose per cycle. This should
be the reference standard for randomized trials comparing new therapies with DTIC [7].
2.2. Temozolomide
Temozolomide (TMZ) is an orally active alkylating agent. It’s a prodrug of MTIC and conge‐
ner of DTIC. It has been available in the US since August 1999 and in other countries since
the early 2000s. The therapeutic benefit of temozolomide depends on its ability to alkylate/
methylate DNA, which most often occurs at the N-7 or O-6 positions of guanine residues.
This methylation damages the DNA and triggers the death of tumor cells. However, some
tumor cells are able to repair this type of DNA damage, and therefore diminish the thera‐
peutic efficacy of temozolomide, by expressing an enzyme called O-6-methylguanine-DNA
methyltransferase (MGMT) or O-6-alkylguanine-DNA alkyltransferase [8].
The single agent activity of TMZ in metastatic melanoma has been established in several
phase 1 and 2 studies [9]. In a randomized trial of 305 patients with advanced melanoma,
TMZ showed efficacy at least equivalent to that of DTIC in terms of objective response rate,
time to progression, and overall disease-free survival [10]. TMZ was tolerated very well and
showed an advantage in terms of improvement in the quality of life. More patients showed
improvement or maintenance of physical functioning at Week 12. That trial excluded pa‐
tients who had brain metastases. Because the trial design was intended to demonstrate the
superiority of TMZ over DTIC, rather than equivalence, the FDA did not accept the results
of that trial as grounds for approving a melanoma indication for TMZ. But in clinical prac‐
tice, patients with metastatic melanoma often are treated off-label with TMZ.
TMZ has demonstrated efficacy in the treatment of variety of solid tumors, especially in
brain malignancies, which is a manifestation of its far greater ability to penetrate the central
nervous system (CNS). Taking into account the high rate of CNS recurrence as a site of fail‐
ure after cytotoxic chemotherapy, TMZ may represent a viable alternative to DTIC, which is
ineffective against melanoma CNS metastases.
2.3. Sorafenib
Sorafenib (BAY43-9006, developed by Bayer Pharmaceuticals, West Haven CT, trade name
Nexavar) is an orally administered tyrosine kinase inhibitor. It is a potent inhibitor of the
BRAF kinase that is frequently mutated in melanoma, as well as an inhibitor of the Vascular
Endothelial Growth Factor (VEGF) receptor and other kinases. It targets the adenosine tri‐
phosphate-binding site of the BRAF kinase and inhibits both wild-type and mutant BRAF in
vitro. Sorafenib was approved by the FDA in December 2005 for use in the treatment of ad‐
vanced renal cancer. Preclinical studies demonstrated a significant retardation in the growth
of human melanoma tumor xenografts with Sorafenib. In a phase 1 study, the maximum tol‐
erated dose of Sorafenib as a single agent was established at 400 mg twice daily, and the
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most common toxicities were gastrointestinal (mainly diarrhea), dermatologic (skin rash,
hand-foot syndrome), and fatigue [11].
But  in  further  phase  2  clinical  trials,  Sorafenib  had  shown  relatively  little  activity  in
metastatic melanoma when using alone. In a phase 2 trial  that was conducted in 20 pa‐
tients with refractory metastatic melanoma, Sorafenib showed modest activity with 1 par‐
tial  response  and  3  patients  who  achieved  stable  disease  [12].  In  another  phase  2,
randomized, discontinuation trial,  no objective responses were achieved, and 19% of pa‐
tients achieved stable disease [13].
Sorafenib combined with other chemotherapy drugs were also tested clinically. In a phase 1
and 2 study that combined carboplatin and paclitaxel with escalating doses of Sorafenib in
35 patients, a promising response rate of 31% was observed, and another 54% of patients ex‐
perienced stable disease that lasted longer than 3 months. That study recently was updated
to include 105 patients, and the current response rate is 27% [14]. On this basis, 2 phase 3
trials have been launched to assess the efficacy of carboplatin and paclitaxel plus Sorafenib
versus placebo in chemotherapy-naive patients and in previously treated patients. In De‐
cember 2006, Bayer reported the combinations failed to show significant improvement of
progression-free survival in melanoma patients [15].
2.4. Vemurafenib
Vemurafenib established a successful model for extracellular chemotherapeutic targeted
therapy based on deep understanding cancer biology. It’s a paradigm of structured-based
drug development. It was first discovered in 2002 that the protein kinase BRAF is mutated
in about 70% of malignant melanomas and a significant number of colorectal, ovarian and
papillary thyroid cancers, implicating mutated BRAF as a critical promoter of malignancy.
Then scientists determined the structure of the BRAF catalytic domain and identified a class
of BRAF inhibitors that bind to the active conformation of the protein. Further lead series
were developed and crystal structures of complexes combined with molecular modeling
studies have resulted in potent selective inhibitors. Vemurafenib is the first one that went
into clinical trials and gained FDA approval in August 2011.
Vemurafenib (PLX4032/RG7204) is developed by Plexxikon (now part of the Daiichi Sankyo
group and Hoffmann–La Roche) for the treatment of late-stage melanoma. Vemurafenib can
induce programmed cell death in melanoma cell lines. It interrupts the BRAF/MEK step on
the BRAF/MEK/ERK pathway − if the BRAF has the common V600E mutation [16].
Vemurafenib has very impressive single-agent clinical activity, with unprecedented re‐
sponse rates of about 80% and a clear impact on progression-free survival longer than 6
months. An international randomized open-label trial in patients with previously untreated
metastatic or unresectable melanoma with the BRAFV600E mutation led to the FDA approval
of Vemurafenib for melanoma. This clinical trial enrolled 675 patients. 337 patients were
randomly assigned to vemurafenib with 960 mg orally twice daily. 338 patients were ran‐
domly assigned to dacarbazine with 1000 mg/m2 intravenously every three weeks. Treat‐
ment end-points are disease progression, unacceptable toxicity, and/or consent withdrawal.
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Vemurafenib’s efficacy was measured by overall survival (OS), investigator-assessed pro‐
gression-free survival (PFS) and confirmed investigator-assessed best overall response rate.
Overall survival was significantly improved in patients receiving vemurafenib compared
with those receiving dacarbazine. The median survival of patients receiving vemurafenib
had not been reached and was 7.9 months for those receiving dacarbazine. Progression-free
survival (PFS) was also significantly improved in patients receiving vemurafenib. The me‐
dian PFS was 5.3 months for patients receiving vemurafenib and 1.6 months for patients re‐
ceiving dacarbazine. 48.4% for patients who received vemurafenib showed complete or
partial response while only 5.5% patients who received dacarbazine showed complete or
partial response [17].
Arthralgia, rash, photosensitivity, fatigue, alopecia, pruritis, and skin papilloma were ob‐
served  in  at  least  30%  of  patients  treated  with  vemurafenib.  Cutaneous  squamous  cell
carcinomas were detected in approximately 24% of patients.  Other adverse reactions re‐
ported  in  patients  treated  with  vemurafenib  included  hypersensitivity,  Stevens-Johnson
syndrome, toxic epidermal necrolysis, uveitis, QT prolongation, and liver enzyme labora‐
tory abnormalities [18].
2.5. Other single chemotherapy agents
Cisplatin and carboplatin have shown modest activity as single agents in patients with
metastatic melanoma. Cisplatin as single-agent therapy induced a 15% response rate with a
short median duration of 3 months [19]. A response rate of 19% has been reported in 26 che‐
motherapy-naive patients with metastatic melanoma who received carboplatin. In those pa‐
tients, there were 5 partial responses, and thrombocytopenia was the dose-limiting toxicity
[20]. In vitro studies suggested that oxaliplatin may be more active than cisplatin or carbo‐
platin. But a small phase 2 trial in 10 patients who had received and failed prior chemothera‐
py produced no objective responses [21].
The nitrosoureas (carmustine, lomustine, and semustine) induce objective responses in
13~18% patients. They can cross the blood-brain barrier. But at conventional doses, little or
no activity was observed against melanoma brain metastases [22]. Another drawback of the
nitrosureas is they induce prolonged myelosuppression. Despite these, they have been in‐
cluded frequently in multi-agent chemotherapy combinations, presumably for their ability
to penetrate into the CNS and lack of viable alternatives for metastatic melanoma.
The vinca alkaloids (vindesine and vinblastine) have produced responses in approximately
14% of patients [23]. The taxanes have produced responses in 16~17% patients [24]. All of
these response rate data were obtained from phase 2 trials. None of those drugs have been
evaluated as single agents in phase 3 trials. Based on the experience with DTIC, it is likely
that the phase 3 trial objective response rates would be less than the rates reported from
phase 2 trials. All of these drugs are rarely used currently as single-agent therapy in meta‐
static melanoma, but they frequently have been incorporated into combination chemothera‐
py and biochemotherapy regimens.
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2.6. Chemotherapy drug combinations
Theoretically drug combination should be based on laboratory or clinical evidence of syner‐
gistic effect. But since single-agent chemotherapy regimens only provided modest activity
against metastatic melanoma and lack of viable alternatives, many combination regimens
have been evaluated in clinical trials. Initially two-agent combinations were tested in which
DTIC was combined with a nitrosourea, vinca alkaloid, or platinum compound. In most of
these trials, only 10~20% response rates were observed. There was little evidence to suggest
superiority of these combinations compared with DTIC treatment alone [25-27].
In order to improve response rates, more aggressive multi-drug combinations using 3 or 4
different drugs were also tested clinically. Two most widely studied combinations are cis‐
platin, vinblastine, and DTIC (CVD) and the Dartmouth regimen. The latter is a 4-drug com‐
bination consisting of cisplatin, DTIC, carmustine, and tamoxifen (also called CDBT). Both
combinations showed improved response rates that ranged from 30% to 50% in single-insti‐
tution phase 2 studies [28, 29]. But in further randomized phase 3 trials which involved
more patients, they all showed much lower efficiency: In a randomized trial comparing
CVD with single-agent DTIC that involved approximately 150 patients, the CVD arm pro‐
duced a 19% response rate compared with 14% for the DTIC arm, and there was no differen‐
ces in either response duration or survival. In another randomized phase 3 trial, the CDBT
combination was compared with single-agent DTIC. That cooperative group trial involved
240 patients, and the response rate was 10% for the DTIC regimen compared with 19% for
the CDBT regimen (P=0.09). The median survival was 7 months, with no significant differ‐
ence between the 2 treatment arms [6].
The main reason for such discrepancies between the results from single-institution studies
and those from large, multicenter, cooperative trials probably is selection bias. Differences in
performance status, percentages of patients with visceral involvement, and number of meta‐
static sites easily could account for some of the observed differences. In fact, all of those fac‐
tors are known to have an impact on both response rate and survival [30].
Overall, controlled trials have produced no compelling evidence to support the value of
combination chemotherapy, with or without tamoxifen, in patients with metastatic melano‐
ma. Toxicity was substantially greater for the combination regimen, with bone marrow sup‐
pression, nausea, emesis, and fatigue significantly more frequent with CDBT than with
DTIC [6]. So it is difficult to justify the use of either CVD or CDBT instead of single-agent
DTIC or TMZ for the treatment of most patients with metastatic melanoma.
3. Immunotherapy agents
3.1. Interleukin-s (IL-2)
In 1998, the FDA approved intermittent high-dose bolus IL-2 based on its ability to mediate
durable complete response in metastatic melanoma patients [31]. IL-2 is a type of cytokine
immune system signaling molecule, which is a leukocytotrophic hormone that is instrumen‐
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tal in the body's natural response to microbial infection and in discriminating between for‐
eign (non-self) and self. It’s a glycosylated 15,500 dalton single protein molecule. IL-2
mediates its effects by binding to IL-2 receptors, which are expressed by lymphocytes, the
cells that are responsible for immunity. It is one of the only two FDA approved agents for
the treatment of metastatic melanoma. Although the overall response rate is only about 15%
and less than 5% of patients achieve complete remission with IL-2, its performance on mela‐
noma is better than DTIC.
One of the major immunologic effects of IL-2 upon the immune system is to expand the
total  number of T-lymphocytes (CD4+ and CD8+) and to prevent lymphocyte apoptosis.
Another key role of IL-2 is to provide the appropriate cytokine milieu necessary to over‐
come tumor-induced immune tolerance. But the exact molecular and genetic mechanisms
involved in this  complex interaction between the tumor and the host  immune response
is still largely unknown [32].
There is  currently  a  wide spectrum of  dosing schedules  and regimens for  IL-2  therapy,
with the current standard used by most oncologists being 600,000 to 720,000 IU/kg/dose,
given at 8 h intervals. Although the optimal dosing schedule resulting in the best clinical
response is  currently unknown, previous data would suggest  that  the higher dose regi‐
mens as well as the number of total doses received correlates best with clinical response.
Thus, several groups have begun to look at alternative dosing strategies to achieve an in‐
creased  drug  tolerance  and  tolerability  profile,  such  as  the  continuous  infusion  of  IL-2
(18  mIU/m2/day)  over  an  extended  period  of  72  h  [33].  But  the  multiorgan  toxicity  of
many  IL-2  regimens  limits  its  use.  In  addition,  the  tumor-killing  cytotoxic  T  cells  and
natural killer cells, which are the presumed target cells for IL-2, are frequently inefficient
in  the  tumor  environment,  partly  due  to  suppressive  and  apoptosis-inducing  signals
from tumor-infiltrating mononuclear phagocytes [34].
3.2. Interferon α
Interferons (IFNs) are proteins made and released by the cells of most vertebrates in re‐
sponse to the presence of pathogens or tumor cells. They allow communication between
cells to trigger the protective defenses of the immune system that eradicate pathogens or tu‐
mors. IFNs belong to the large class of glycoproteins known as cytokines. They are named
after their ability to "interfere" with viral replication within host cells. IFNs have other func‐
tions: they activate immune cells, such as natural killer cells and macrophages; they increase
recognition of infection or tumor cells by up-regulating antigen presentation to T lympho‐
cytes; and they increase the ability of uninfected host cells to resist new infection by virus.
Based on the type of receptors through which they signal, human interferons have been clas‐
sified into three major types. The type I interferons present in human are IFN-α, IFN-β and
IFN-ω [35]. High-dose IFN therapy using IFN-α was the first form of medical therapy to be
approved by the FDA for use in high-risk melanoma in the adjuvant setting. Adjuvant nor‐
mally means using IFN- α weeks after the surgical excision of the melanoma tumor. Com‐
mon treatment scheme is IFN-α2b at 20 million units (MU)/m2/day intravenous injection 5
days a week for 4 weeks, then 10 MU/m2/day subcutaneous injection 3 days a week for the
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next 48 weeks for a full year’s. But IFN-α2b can also be used one month before definitive
surgical lymphadenectomy. This is called ‘neoadjuvant’ treatment [36].
The first randomized comparison of high-dose IFN versus observation found the median re‐
lapse-free survival was 1.72 years in the high-dose IFN arm versus 0.98 year in the observa‐
tion arm (P=0.0023) and the median overall survival was 3.82 versus 2.78 years (P=0.0237)
respectively [37]. But in a later pooled analysis of more patients in more clinical trials, the
relapse-free survival benefit was maintained but no overall survival benefit was seen [38].
The exact mechanism of IFN IFN-α’s anti-tumor efficacy is still unknown. But it was found
that the STAT1/STAT3 expression ratios rose in association with IFN treatment. The clinical
effects of IFN-α2b in human melanoma are also found to be inversely related to STAT3 ex‐
pression (41). Induction of apoptosis has been shown to be important in vitro, if not in vivo.
IFN-α can induce apoptosis in transformed cell lines as well as primary tumor cells [39].
High-dose IFN is the standard of care for high-risk melanoma patients in the adjuvant set‐
ting. However, it is associated with significant toxicity. The incidence and severity of these
adverse events is clearly dose-related. Consequently, there has been a great deal of interest
in intermediate- and low-dose regimens administered through subcutaneous injection.
However, none of the trials using intermediate or low dosing so far have been able to dem‐
onstrate any reliable benefit in terms of relapse-free survival or overall survival [40].
3.3. Pegylated interferon-α2b
Pegylated interferon-α2b gained its approval from the FDA in March 2011 in the adjuvant
setting for melanoma patients with lymph-node-positive disease (stage III) after lymph-
node dissection. The approval was based on a randomized controlled phase-III trial in 1256
stage-III melanoma patients. This trial compared treatment with pegylated interferon- α2b
for up to 5 years with observation. The results revealed a significant and sustained impact
on relapse free survival (RFS) in the intention-to-treat (ITT) population. This trial also
showed that interferon-α2b treatment didn’t significantly improve distant metastasis-free
survival (DMFS) or overall survival (OS) [41]. Pegylated interferon-α2b also showed much
better effect in patients with sentinel-node-positive disease (stage III-N1: microscopic in‐
volvement only) compared with patients with palpable nodal disease (stage III-N2). It also
significantly improved DMFS in sentinel-node-positive patients in contrast to a marginal ef‐
fect in patients with palpable nodes. The authors identified tumor stage as a predictive fac‐
tor in trials. One very important finding from clinical trials was that ulceration of the
primary melanoma indicated a distinct biology that was clearly IFN sensitive in contrast to
the non-ulcerated type of melanoma.
3.4. Anti-CTLA4 antibodies: Ipilimumab and tremelimumab
Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) also known as CD152 (Cluster of differentia‐
tion 152) is a member of the immunoglobulin super family, which is expressed on the sur‐
face of Helper T cells and transmits an inhibitory signal to T cells that eventually shuts off
the activated state. The rationale for involving this in treatment of metastatic melanoma is to
Melanoma - From Early Detection to Treatment544
block the negative signal sending by CTLA4 by using anti-CTLA4 antibodies, thus reduce
the sensitivity of activated T cells to negative regulatory signals and enhance the immune
response of the host to tumor cells.
As of October 2007 there are two fully human monoclonal anti-CTLA4 antibodies in ad‐
vanced clinical trials, one from Medarex, Inc. (Princeton, NJ) and Bristol-Myers Squibb (New
York), called ipilimumab (MDX-010), and one from Pfizer (New York), called tremelimumab
(formerly ticilimumab, CP-675,206) [42]. These antibodies were produced using different
types of mice with engineered immune systems, and are thus fully human, with long half-
lives of 2– 4 weeks.
Ipilimumab (MDX-010) is an IgG1 monoclonal antibody. Preclinical and early clinical stud‐
ies of patients with metastatic melanoma show that ipilimumab promotes antitumor activity
as monotherapy and in combination with treatments such as chemotherapy, vaccines, or cy‐
tokines. The initial success with these antibodies has encouraged the rapid development of
new agonistic and antagonistic antibodies that alter immune regulation, such as anti-PD-1,
anti-4-1BB, anti-CD40, and anti-OX-40. On December 10, 2007, Bristol-Myers Squibb and
Medarex released the results of three studies on ipilimumab [42]. The three studies tested
487 patients with metastatic melanoma. Short-term tumor progression prior to delayed re‐
gression has been observed in ipilimumab-treated patients, and objective responses may be
of prolonged duration. In some patients clinical improvement manifests as stable disease,
which may also extend for months or years. One of the three studies failed to meet its pri‐
mary goal of shrinking tumors in at least 10% of the study's 155 patients. Overall the medi‐
cation produced weaker-than-anticipated efficacy on melanoma patients.
In the meantime, the side effect profile was high in the ipilimumab treated group, with the
generation of autoimmune-like effects, such as diarrhea, dermatitis and effects upon the thy‐
roid and pituitary glands. Several patients also experienced vitiligo, indicative of anti-mela‐
nocyte autoimmunity. However, the majority of the side effects were noted to be transient
(except the vitiligo), improving or disappearing after the completion of therapy. Early clini‐
cal data suggest a correlation between these side effects and response to ipilimumab treat‐
ment and most likely reflect the drug mechanism of action and corresponding effects on the
immune system [42].
In 2011, the first-line pivotal trial data for ipilimumab was released. The median survival of
patients treated with ipilimumab at a dose of 10 mg/kg in combination with dacarbazine
was 11.2 months. Patients treated with dacarbazine alone showed a median survival of 9.1
months. The improvement in the median survival was 2.1 months. The estimated survival
rates in the two groups of, respectively, 47.3% and 36.3% at 1 year, 28.5% and 17.9% at 2
years, and 20.8% and 12.2% at 3 years. These results are not better than those observed with
the 3 mg/kg dose in second-line treatment. One possible reason is that a significant and un‐
expectedly high rate of hepatitis in the dacarbazine + ipilimumab arm did take a significant
percentage of patients off treatment before the third or especially the fourth dose of ipilimu‐
mab could be administered, thus limiting both the number of administrations of dacarba‐
zine as well as of ipilimumab in the combination arm. Other immune-related adverse events
were not increased compared to those with the 3 mg/kg dose experience. The overall inter‐
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pretation therefore is that dacarbazine did not help, but may rather have mitigated the re‐
sults in the dacarbazine plus ipilimumab arm. Based on all the data available, the large
cumulative phase-II experience, and the two phase-III trials, the FDA approved treatment of
melanoma with ipilimumab alone at the 3mg/kg dose [43].
Tremelimumab is an IgG2 monoclonal antibody produced by Pfizer. It blocks the binding of
the antigen-presenting cell ligands B7.1 and B7.2 to CTLA-4, resulting in inhibition of B7-
CTLA-4-mediated down-regulation of T-cell activation. Subsequently, B7.1 or B7.2 may in‐
teract with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated
T-cell activation unopposed by B7-CTLA-4-mediated inhibition. Tremelimumab is thought
to stimulate patients’ immune systems to attack their tumors. It has been shown to induce
durable tumor responses in patients with metastatic melanoma in phase 1 and phase 2 clini‐
cal studies [44].
On April 2, 2008, Pfizer announced that it has discontinued a phase 3 clinical trial for pa‐
tients with metastatic melanoma after the review of interim data showed that the trial would
not demonstrate superiority to standard chemotherapy [45]. Studies for other tumors are
planned as of October 2009, namely for prostate cancer and bladder cancer.
3.5. Anti-integrin antibody: Etaracizumab
Etaracizumab (also known as etaratuzumab, MEDI-522, trade name Abegrin) is an IgG1
humanized monoclonal antibody directed against the αVβ3 integrin. αVβ3 is essential for
endothelial cell proliferation, maturation, and survival. When it is blocked, proliferating en‐
dothelial cells undergo apoptosis and regress. In addition, αVβ3 is highly expressed in mela‐
nomas and is associated with tumor growth and invasion. In preclinical studies using αVβ3
antagonists, inhibition of melanoma tumor growth independent of its antiangiogenic effects
was reported [46]. Etaracizumab has been investigated in 3 phase 1, dose-escalation studies
in patients with refractory melanoma. In the phase 2 trial, 57 patients received etaracizumab
alone, and 55 patients received etaracizumab plus DTIC. Etaracizumab with or without
DTIC generally was well tolerated and was active in patients with metastatic melanoma.
The median survival was 12.6 months for the group that received etaracizumab with DTIC
and 9.4 months for the group that received etaracizumab without DTIC [47]. These results
encouraged people to further test this antibody in more clinical trials.
Early 2010, a study by the Etaracizumab Melanoma Study Group was reported. In this
study, 112 patients were randomized to receive etaracizumab alone or etaracizumab plus
DTIC. None of the patients in the etaracizumab alone study arm and 12.7% of patients in the
etaracizumab plus DTIC study arm achieved an objective response. Stable disease occurred
in 45.6% of patients in the etaracizumab alone study arm and 40.0% of patients in the etara‐
cizumab plus DTIC study arm. Despite a modest increase in survival, 12.6 months in the
etaracizumab alone arm, versus 9.4 months in the etaracizumab plus DTIC arm, the re‐
searchers concluded that the survival results in both treatment arms of this study were con‐
sidered unlikely to result in clinically meaningful improvement over DTIC alone [48]. At the
present time, clinical development of etaracizumab has been interrupted.
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3.6. Vaccines based on tumor cells: Canvaxin, melacine, and MVax
The basic idea is to use tumor cell-based vaccine to stimulate and activate the host immune
system to recognize, contain and eliminate cancer cells. This effect may be based on the fol‐
lowing two pathways: direct migration of the tumor cells to the draining lymph node basin
after injection, or uptake of apoptotic or necrotic tumor cells by host dendritic cells located
within the skin [49].
The most extensively studied tumor cell-based vaccine is a polyvalent, antigen-rich whole
cell vaccine called Canvaxin (CancerVax Corp., Carlsbad, CA). It is comprised of three mela‐
noma cell lines that contain over 20 immunogenic melanoma tumor antigens, given intra‐
dermally every two weeks for 3 to 5 doses, followed by monthly injections for the remainder
of the first year. However, several small, single-institution phase 1 and 2 clinical trials of
Canvaxin have not yielded a striking clinical benefit in most patients when administered
with BCG as an immunoadjuvant [50]. But the rare complete responder to Canvaxin therapy
has prompted the initiation of two multicenter phase 3 randomized trials of Canvaxin thera‐
py in 1998. In these trials, patients who have undergone complete resection of regional
(stage III) or distant (stage IV) metastatic melanoma receive postoperative adjuvant immu‐
notherapy with Canvaxin plus Bacillus of Calmette and Guerin (BCG) or BCG alone. In
April 2005, CancerVax announced the discontinuation of their phase 3 clinical trial of Can‐
vaxin in patients with Stage IV melanoma based upon the clinical funding that it was un‐
likely that the trial would provide significant evidence of a survival benefit for Canvaxin-
treated patients versus those receiving placebo. On October 3, 2005, CancerVax announced
the discontinuation of another phase 3 clinical trial of Canvaxin in patients with Stage III
melanoma base on a similar reason [51].
The second tumor cell-based vaccine that has been well studied since 1988 is Melacine. It
is an allogeneic melanoma cell  lysate combined with an immunologic adjuvant which is
composed  of  a  mixture  of  detoxified  endotoxin,  cell  wall  cytoskeleton  and  monophos‐
phoryl lipid A. Early phase 1 and 2 clinical trials in 1987 and 1988 revealed some prom‐
ising results,  with  one  complete  and three  partial  responses  seen in  25  patients  treated
with Melacine. These results prompted the completion of seven open-label phase 2 trials
involving 139 patients with stage III/IV melanoma and a multicenter phase 3 clinical trial
of  Melacine  versus  the  Dartmouth  regimen.  The  objective  response  rates  for  all  of  the
above  studies  have  been  between  5  and  10%.  Based  largely  upon  these  former  results
and the  clinical  results  of  other  phase  3  trials,  a  phase  3  observation controlled trial  of
Melacine in melanoma patients was conducted. But the results revealed no evidence of a
benefit from Melacine in patients with melanoma [52].
One very promising autologous cell vaccine is MVax which is now in active phase 3 clinical
trial sponsored by AVAX Technologies, Inc. This vaccine is derived from autologous tumor
cells that have been irradiated and then modified with the hapten dinitrophenyl (DNP) [53].
In February 2004 the Journal of Clinical Oncology published an article by Dr. David Berd on
the treatment of 214 Stage IIIb and IIIc melanoma patients that showed a five-year survival
rate of 44%. Comparison to published results of similar patients treated with surgery alone
showed five-year survival figures of 22%. In stage IV patients MVax has demonstrated sig‐
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nificant response rates as a monotherapy and in published reports MVax plus adjuvant IL-2
have reported response rate of 35% (13% Complete Response, 22% Partial Response). This
compares to published response rates in low dose IL-2 of 3% [54].
In October 2006, AVAX obtained a Special Protocol Assessment (SPA) agreement with the
FDA for its phase 3 protocol. The SPA allows for the start of the phase 3 registration clinical
trial for MVax for the treatment of patients with metastatic melanoma. In addition, the SPA
addressed AVAX’s ability to use a surrogate endpoint as a basis for accelerated approval.
Based on this SPA, a phase 3 trial for stage IV melanoma was started on May 2007. AVAX
plans to enroll up to 387 patients who will be assigned in a double-blind fashion at a 2:1 ra‐
tio to MVax or placebo vaccine. The MVax arm will consist of an initial dose of MVax fol‐
lowed by cyclophosphamide and then six weekly doses of MVax administered with BCG.
Following vaccine administration patients will receive a specific schedule of low dose IL-2.
Patients assigned to the control group will receive a treatment identical to the MVax group,
except that a placebo vaccine will replace MVax. The primary endpoints of the study are
best overall anti-tumor response rate and the percentage of patients surviving at least 2
years. Secondary endpoints of the study will include overall survival time, response dura‐
tion, percentage complete and partial responses, progression free survival and treatment re‐
lated adverse events [55].
3.7. Vaccines based on peptides: MDX-1379, astuprotimut-R, and others
The identification of tumor antigens that are present on the surface of melanoma cells is the
basis for developing cancer vaccines that utilize peptide based immunotherapy. There are
several melanoma differentiation antigens known involved in the synthesis of melanin and
recognized by melanoma-reactive T cells, for example, gp100, MART-1/Melan-A, tyrosinase,
TRP-1 and TRP-2, NY-ESO-1and the melanoma-associated antigen (MAGE) etc. One big ad‐
vantage of peptide based-vaccination is that it has few toxic side effects or adverse reactions.
Data suggests that most tumor cell lines established from fine needle aspiration biopsies of
patients with metastatic melanoma exhibit a relatively homogeneous co-expression of
MART-1 and tyrosinase, with a much more heterogeneous expression of other tumor anti‐
gens, such as gp100, NY-ESO 1 and the MAGE antigens [56].
Rosenberg and his colleagues developed a with a peptide based-vaccine using modified
immunodominant peptide of the gp100 antigen, g209-2M. They used this agent vaccinat‐
ed stage IV melanoma patients subcutaneously every three weeks. Following two immu‐
nizations,  10  of  11  (91%)  of  patients  showed a  consistently  high  level  of  immunization
against  the  native  g209~217  peptide,  but  not  against  the  control  peptide  g280~288.  This
study also demonstrated that the majority of patients immunized with the g209-2M pep‐
tide in incomplete Freund’s adjuvant (IFA) consistently developed high levels of circulat‐
ing  immune  precursors  reactive  against  the  native  g209~217  peptide.  Clinically,  one  of
nine patients who received the g209~217 peptide in IFA experienced an objective cancer
regression that  lasted 4 months.  Three of  the eleven patients  exhibited mixed responses
with  complete  or  partial  regression  of  several  lesions.  However,  all  patients  eventually
developed progressive disease [57].
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MDX-1379 vaccine consists of two gp100 melanoma peptides. These peptides are part of a
protein normally found on melanocytes, or pigmented skin cells, and on melanoma cells.
These melanoma peptides are recognized by cytotoxic T cells in melanoma patients that are
positive for HLA-A2, a human immune system compatibility antigen that is expressed in
approximately half of the melanoma population. Phase II data show limited evidence of
MDX-1379's clinical activity although there is strong proof-of-concept for therapeutic vac‐
cines based on gp100 in melanoma. Medarex is currently conducting a phase 3 clinical trial
with ipilimumab and MDX-1379 combination therapy in stage III and IV melanoma at mul‐
tiple sites within the United States. Preliminary data showed MDX-1379 plus ipilimumab in‐
duced a modest percentage of durable response in stage IV melanoma. But autoimmune
events could make the risk/benefit ratio for MDX-1379 plus ipilimumab unfavorable [58].
Astuprotimut-R (also called recombinant MAGE-A3 antigen-specific cancer immunothera‐
peutic GSK1203486A) is a cancer vaccine consisting of a recombinant form of human mela‐
noma antigen A3 (MAGE-A3) combined with a proprietary adjuvant with potential
immunostimulatory and antineoplastic activities. Upon administration, astuprotimut-R may
stimulate a cytotoxic T-lymphocyte response against tumor cells expressing the MAGE-A3
antigen, resulting in tumor cell death. MAGE-A3, a tumor-associated antigen (TAA) origi‐
nally discovered in melanoma cells, is expressed by various tumor types including melano‐
ma, non-small cell lung cancer, head and neck cancer, bladder cancer, with no expression in
normal cells. MAGE-A3 protein has been in-licensed by GlaxoSmithKline (GSK) from the
Ludwig Institute for Cancer Research. The proprietary immunostimulating adjuvant in this
agent is composed of a specific combination of immunostimulating compounds selected to
increase the anti-tumor immune response to MAGE-A3. Using this vaccine as intramuscular
administration together with GSK’s two proprietary adjuvant systems, AS15 or AS02B, they
have developed a treatment regimen for cancer patients called Antigen-Specific Cancer Im‐
munotherapeutic (ASCI).
In 2008, GSK reported a randomized, open-label phase 2 study designed to evaluate Astu‐
protimut-R. A total of 72 patients with measurable metastatic MAGE-A3-positive cutaneous
melanoma (unresectable or in transit stage III or stage IV M1a) were randomized to receive
immunization with MAGE-A3 protein combined with either AS15 or AS02B as first-line
metastatic treatment. Patients were to receive a maximum of 24 immunizations over four
years. Clinical activity is assessed by the Response Evaluation Criteria In Solid Tumors (RE‐
CIST) criteria, the international standards for evaluation of solid tumors. Complete response
(CR) and partial response (PR) i.e., disappearance or significant reduction of tumor, were re‐
ported in 4 patients in the AS15 group (3 CR and 1 PR) with two of these ongoing for more
than two years; in the AS02B arm, 1 patient showed a partial response which lasted for 6
months. The safety profile was similar in both groups with the majority of reported adverse
events being mild or moderate local or systemic reactions [59]. Currently this agent still is
under phase 2 clinical development for progressive metastatic cutaneous melanoma.
Because melanoma tumors are heterogeneous in their antigenic profile, it is very difficult to
make vaccines that can elicit cytotoxic T-cell responses universally in all the host immune
systems. Rosenberg’s group analyzed 28 different peptide-based vaccines utilized in stage
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IV melanoma patients. A total of 381 patients were treated with 370 patients showing no re‐
sponse, 9 patients showing a partial response and 2 patients with a complete response, for
an overall objective response rate of only 2.9%. This suggested the lack of effectiveness with
this single peptide based vaccination approach [60].
Next logical step is to make vaccines with multiple peptides to overcome tumor cell antigen‐
ic heterogeneity. A recent randomized phase 2 trial was performed in 26 patients with meta‐
static melanoma, vaccinating with four melanoma peptides. Although a high level of
specific T-cell responses were noted (in 42% of the peripheral blood, 80% of sentinel lymph
nodes), only three patients had a clinical response [61].
Here is the biggest issue in this area, actually many peptide based-vaccinations have result‐
ed in a significant increase in the number of lymphocyte precursors reactive against a varie‐
ty of tumor differentiation antigens by immunization with native or modified peptides.
However, such immunological responses to peptide-based therapy have not translated into
meaningful clinical responses for the vast majority of patients. To date, there is no study that
has clearly shown a direct correlation between an immunologic response to therapy (im‐
mune cell activation) and a clinical response (regression of established tumor).
3.8. Vaccines based on dendritic cells
In the normal human epidermis and dermis, dendritic cells (DC) are present as relatively
immature antigen presenting cells, exhibiting relatively low levels of class II major histo‐
compatibility complex (MHC) molecules and co-stimulatory molecules. But these immature
DC are quite capable of capturing various soluble protein antigens, such as apoptotic and
necrotic tumor cells and then cross-presenting such tumor-associated antigens to cytotoxic
CD8+ T cells. When relatively immature DC in the skin is triggered to enter afferent lym‐
phatic channels, this migrating pathway also initiates a phenotypic conversion that has pro‐
found immunological consequences [30]. When the DC arrives in the lymph node, it is
characterized by an abundant levels of class II MHC antigens, as well as high surface levels
of costimulatory molecules, such as CD40, CD54, CD80, CD83, and CD86. The matured DC
is then capable of forming stable MHC class II-peptide complexes available to activate anti‐
gen specific CD4+ T cells [62].
To make the dendritic cell-based vaccine, the monocyte-derived, autologous DC can be
pulsed in vitro with either whole irradiated, autologous tumor cells or tumor cell lysate.
Once the tumor cells are “fed” to the DC in vitro, the apoptotic or necrotic cells are then
processed and tumor-specific peptide antigens are then transported to the surface in both an
MHC class I- and II-restricted fashion. Both immature and mature DC can be administered
to patients as vaccine safely with few adverse side effects. The administration of DC via var‐
ious routes of vaccination (intradermal, intranodal and intravenous) is also feasible. The first
published clinical trial of DC vaccination was in 1995 and has since been followed by 98 ad‐
ditional clinical trials describing more than 1,000 DC-based vaccines performed in 15 differ‐
ent countries. Twenty-eight trials focused on patients with various advanced stages of
melanoma. The safety profile was again noted to be quite remarkable, however, despite the
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treatment of over 1,000 patients with DC-based vaccines, the record of effectiveness have
been disappointing [63].
One very successful DC-based trial for patients with advanced, metastatic melanoma was
reported by Nestle et al. He used plastic adherent monocytes matured with a xenogeneic-
based 10% fetal calf serum, subsequently pulsed with either tumor cell lysate or multiple
HLA-matched peptides injected intranodally. This trial involved 16 patients who were im‐
munized on an outpatient basis. Overall, 5 of 16 patients experienced an objective response,
2 complete and 3 partial responses. The side effects were noted to be minimal in all cases,
with the development of vitiligo in a few patients. One dramatic feature of this treatment
was the durability of the clinical responses, with the 2 complete responders remaining free
of disease for over 15 months [64].
One phase 3 clinical trial about using DC-based vaccine to treat metastatic melanoma was
report by Schadendorf and colleagues recently [65]. The trial was a prospective, randomized
trial that analyzed the therapeutic effects of an autologous peptide-pulsed DC-based vaccine
in patients with stage IV melanoma compared to standard chemotherapy with DTIC alone.
The results revealed that the overall response in the vaccine group was 3.8% compared to
5.5% in the DTIC group, with no statistically significant differences noted in response, toxici‐
ty, overall and progression-free survival between the two groups. The median time to pro‐
gression was 2.8 months versus 3.2 months respectively and the median survival was 11
months for the DTIC arm but only 9 months for the vaccine arm [65].
Although disappointed by many trials, several new avenues of DC-based immunotherapy
are actively being pursued and in various stages of development, focusing on different ways
to enhance the therapeutic efficacy of DC in combination with various immunoadjuvants
and other anticancer agents.
3.9. Individual therapy based on activated T-cells
One very promising approach to treat metastatic melanoma is to use fully activated anti-tu‐
mor T-cells as warhead. This regimen involves the adoptive autologous transfer of highly
selective tumor-reactive T-cells directed against over-expressed self-derived differentiation
antigens after lymphodepleting chemotherapy. Rosenberg group reported in 2004 a clinical
trial using this method. Cancer regression in patients with refractory metastatic melanoma
with large, vascularized tumors was noted in a remarkable 18 of 35 patients (51% response
rate), including four patients with a complete regression of all metastatic disease. Such re‐
sults may stem from the ability to infuse a large number of fully activated tumor infiltrating
lymphocytes with anti-tumor activity into a host that is depleted of regulatory T-cells [66].
4. Gene therapy agents
The recent developments in the field of gene transfer have advanced the use of gene therapy
as a novel strategy against a variety of human malignancies. Because of its unique set of
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characteristics, melanoma represents a suitable target for gene therapy. Several strategies
have been used by gene therapy to treat melanoma. First is to target melanoma cells to intro‐
duce "suicide" genes. Second is to transfer tumor suppressor genes. Third is to inactivate
aberrant oncogene expression. Fourth is to introduce genes encoding immunologically rele‐
vant molecules. Last is to target the host's immune cells to redirect immune responses
against melanoma. Clinical trials have shown the feasibility and safety of gene therapy
against malignant melanoma. Although no major successes have been reported, the positive
results observed in some patients support the potential for gene therapy in the management
of this disease. To make gene therapy as an effective modality of treatment for malignant
melanoma, better vector technology as well as increased understanding of the "bystander ef‐
fect" triggered by gene transfer approaches are needed [67].
The gene therapy in our discussion is to introduce oligonucleotide or DNA sequence into
host body thus to stimulate immune response to tumor cells. So it is also called DNA vacci‐
nation. This approach has been shown to induce long-lasting immunity against infectious
agents and protection from tumor outgrowth in several animal models [68]. Likewise, intra‐
muscular injections of DNA (composed of naked DNA expression plasmids) into humans
have also resulted in the development of an immunologic response [69]. It is hypothesized
that one mechanism of tumor antigen expression may involve the DNA introducing the ap‐
propriate genes into dendritic cells for subsequent processing and presentation to the host
immune system. One of the obvious advantages of DNA vaccinations is that they can be ad‐
ministered to patients regardless of HLA-phenotype and without identifying immunogenic
epitopes.
4.1. Anti-BCL2 antisense oligonucleotide genasense
Genasense (Oblimersan sodium developed by Genta Inc. which is a biopharmaceutical com‐
pany based in Berkeley Heights, New Jersey) is a phosphorothioate antisense oligonucleo‐
tide directed against the first six codons of the Bcl-2 messenger RNA. Binding of the drug to
the mRNA recruits RNAse H, resulting in cleavage of the mRNA. As a result, further trans‐
lation is halted and intracellular protein concentrations of Bcl-2 decrease with time. Melano‐
ma cell lines having Bcl-2 overexpression have been shown to enhance activity of
metastasis-related proteinases, in vitro cell invasion, and in vivo tumor growth [70]. Many in
vitro studies have demonstrated increased sensitivity of melanoma cells to chemotherapy
when combined with antisense Bcl-2 therapy [71]. Genasense is the first oncology drug of its
kind to directly target the biochemical pathway (known as apoptosis) whereby cancer cells
are ultimately killed by chemotherapy. Genasense is believed to inhibit the production of
Bcl-2, a protein that is believed to be a fundamental cause of resistance to anticancer thera‐
py. By inhibiting Bcl-2, Genasense may greatly improve the activity of anticancer therapy.
Encouraged by previous data, numerous clinical trials were started to evaluate the addition
of oblimersan to chemotherapy in various solid tumors, including melanoma. Updated anal‐
ysis from a randomized phase 3 trial, comparing DTIC combined with oblimersan, with
DTIC alone in 771 patients with Stage IV or unresectable Stage III melanoma who had not
previously received chemotherapy has shown a response rate of 12.4% in the former com‐
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pared with 6.8% in the latter group (P=0.007) [72]. Median progression-free survival for the
oblimersan group was 2.4 months as compared with 1.6 months for the DTIC group, with a
relative risk reduction of 27% (P=0.0003). The median survival was increased from 7.8
months in the DTIC arm to 9 months in the oblimersan arm with a P value of 0.077, which
became significant when the patients with normal baseline LDH were analyzed. In terms of
toxicity, no new or unexpected adverse events were observed in this study, which had not
been seen with DTIC alone.
However, in May 2004, a new drug application (NDA) based on 6-months of minimum fol‐
low-up data from this trial failed to receive an affirmative vote for approval by an advisory
committee to the FDA. Genta subsequently withdrew that application, and the Company
has not yet made a decision regarding re-filing the U.S. application [73].
4.2. DNA Plasmid-lipid complex allovectin-7
Allovectin-7  is  a  bicistronic  plasmid formulated with  a  cationic  lipid  system containing
the DNA sequences encoding HLA-B7 and beta-2 microglobulin,  which together form a
MHC1 antigen. Injection of Allovectin-7 directly into tumors is designed to stimulate an
immune response against both local and distant metastatic tumors. Allovectin-7 is a nov‐
el  gene  therapy approach for  cancer  with  a  unique mechanism of  action that  is  funda‐
mentally different from currently approved treatments.  The following three mechanisms
were believed to play roles in this agent’s efficacy. Mechanism one, in HLA-B7 negative
patients,  a  vigorous  allogeneic  immune  response  may  be  initiated  against  the  foreign
MHC class I  antigen. Mechanism two, in all  patients,  ß2 microglobulin may reconstitute
normal class I antigen presentation and/or increase tumor antigen presentation to the im‐
mune system.  Mechanism three,  in  some patients,  an innate  pro-inflammatory response
may  occur  that  induces  tumor  responses  following  intralesional  injection  of  the  DNA/
lipid complex. The final outcome of all these mechanisms is to initially cause recognition
of  the  tumor at  the  local  site  to  allow a  then sensitized immune response  to  recognize
un-injected tumors at distant metastatic sites [74].
In 2001, Dr. Richards and his colleagues began a high-dose, 2 mg, phase 2 trial evaluat‐
ing the Allovectin-7 immunotherapeutic alone for patients with stage III or stage IV mel‐
anoma,  who  have  few  other  treatment  options.  The  high-dose  phase  2  trial  completed
enrollment  in 2003.  The data showed that  the trial  had a total  of  15 responders among
the 127 patients  receiving the high dose (11.8%),  with four  of  the  patients  having com‐
plete responses and 11 having partial responses. The Kaplan-Meier estimated median du‐
ration of response was 13.8 months.  The Kaplan-Meier median survival was 18 months.
The safety profile was excellent with no reported Grade 3 or Grade 4 adverse events as‐
sociated with Allovectin-7 [75].
Allovectin-7 has been granted orphan drug designation for the treatment of invasive and
metastatic melanoma by the FDA’s Office of Orphan Products Development. Orphan drug
designation provides U.S. marketing exclusivity for seven years if marketing approval is re‐
ceived from the FDA
Therapeutic Agents for Advanced Melanoma
http://dx.doi.org/10.5772/53632
553
Vical is conducting the AIMM (Allovectin-7 Immunotherapeutic for Metastatic Melanoma)
trial, a phase 3 pivotal trial of Allovectin-7 as first-line therapy in approximately 375 patients
with Stage III or IV recurrent metastatic melanoma in accordance with a SPA agreement
completed with the FDA. The trial is being conducted at approximately 60 clinical sites
worldwide. They designed the trial to include patients most likely to benefit from our treat‐
ment, and specifically excluded patients with brain or liver metastases, patients previously
treated with chemotherapy, and patients with elevated lactate dehydrogenase (LDH) levels.
In January 2010 Vical announced that the company has completed enrollment of the plan‐
ned 375 subjects in its multinational phase 3 trial of Allovectin-7 in patients with metastatic
melanoma. Allovectin-7®’s safety profile is excellent with no drug-related serious adverse
events reported to date in the phase 3 trial [74].
4.3. Herpes simplex virus based oncoVEX
OncoVEX (GM-CSF) is an enhanced potency, immuneenhanced oncolytic herpes simplex vi‐
rus type 1 (HSV-1). It is deleted for infected-cell protein gene 34.5 (ICP34.5), providing tu‐
mor selective replication, and ICP47 gene which otherwise blocks antigen presentation. In
addition, ICP47 deletion increases unique short region protein 11 (US11) gene expression
thereby enhancing virus growth and replication in tumor cells. The coding sequence for hu‐
man granulocyte-macrophage colony-stimulating factor (GM-CSF) is inserted, replacing
ICP34.5, to enhance the immune response to tumor antigens released following virus repli‐
cation.
OncoVEX is developed by BioVex (Woburn, MA). It is a first-in-class oncolytic, or cancer de‐
stroying virus, that works by replicating and spreading within solid tumors (leaving healthy
cells unaffected), thereby causing cancer cell death and stimulating the immune system to
destroy un-injected metastatic deposits. Both modes of action have been clearly validated in
the clinic, where multiple patients with metastatic disease progressing at enrollment have
been declared disease free.
BioVex recently concluded a 50-patient phase 2 trial for OncoVEX (GM-CSF) as a stand-
alone therapy in patients with Stage IIIc and Stage IV melanoma. The trial was designed to
measure overall objective response, which is defined as a complete response, where disease
is completely eliminated, or partial response, where there is a >50% reduction in disease bur‐
den. 74% of patients who entered the study were progressing after having failed prior thera‐
py. 13 objective systemic responses (26% objective response rate) were achieved including
eight CRs, seven of which remain free of disease. 12 responses have so far continued for
more than 6 months (ranging from 6 to more than 29 months). Responses were observed in
patients with all stages of disease, including the complete resolution of un-injected visceral
deposits. Adverse effects were primarily limited to transient flu-like symptoms [76].
In April 2009, BioVex Inc. announced that its OPTiM (OncoVEX Pivotal Trial in Melanoma)
phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and
Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S.
and with sites in the United Kingdom, Germany and Australia. The OPTiM trial is a multi-
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national, open label, randomized study designed to assess the efficacy and safety of treat‐
ment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in
patients with unresectable stage III (b-c) and stage IV (M1a-c) disease. Patients will have re‐
ceived at least one prior therapy for active disease which includes any type of therapy in‐
cluding investigational drugs. A total of 360 patients will be enrolled (240 to the OncoVEX
(GM-CSF) arm and 120 to the control arm). The study design was agreed with the FDA un‐
der the special protocol assessment process [77].
5. Possible reasons for extremely high resistance of metastatic melanoma
Despite an epic number of clinical trials to test a wide variety of anticancer strategies, the
average survival rate for patients with metastatic melanoma remains unimproved during
the past 30 years (41). Though constant clinical trials effort, although some approaches
showed promising intermediate results, still no agent has been granted FDA approval for
the treatment of metastatic melanoma. There are several reasons that may account for the
extremely high resistance of metastatic melanoma to current treatment modalities.
5.1. Reasons for chemotherapy resistance
Melanoma cells are quite resistant to most chemotherapy reagents. This is associated with
the specific feature of melanoma cells. In nature, these cells have low levels of spontaneous
apoptosis in vivo compared with other tumor cell types, and they are relatively resistant to
drug-induced apoptosis in vitro [78]. The natural role of melanocytes is to protect inner or‐
gans from UV light, a potent DNA damaging agent. Therefore, it is not surprising that mela‐
noma cells may have special DNA damage repair systems and enhanced survival properties
[79]. Moreover, recent studies showed that, during melanoma progression, it acquired com‐
plex genetic alterations that led to hyperactivation of efflux pumps, detoxification enzymes,
and a multifactorial alteration of survival and apoptotic pathways. All these have been pro‐
posed to mediate the multi-drug resistant phenotype of melanoma [80].
5.2. Barriers for successful immunotherapy
The major barrier is immunosuppressive effects activated by tumors. Tumor cell can escape
immune rejection and induce immunosuppression through the following five major paths.
Firstly, tumor cells may lose or down-regulate either the melanoma associated antigens or
MHC molecules. Secondly, tumor cells may produce a plethora of immunosuppressive fac‐
tors such as interleukin-10, VEGF and transforming growth factor. These factors create an
inherently unfavorable microenvironment that limits the host immune response, in addition
to tolerating the T-cell response to established tumor. Third possible reason is intrinsic inef‐
ficiency of DC whereby the appropriate co-stimulatory molecules are not being presented
on the cell surface. Fourth possible reason is tumor-related alterations in T-cell signaling and
a skewing of the immune response from a Th1 (immunoactivating) to a Th2 response (im‐
munotolerant). Lastly, the concept of tumor cell escape and immune tolerance is an exceed‐
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ingly complex process. We need to further understand these mechanisms before we can
have successful immunotherapy to melanoma [32].
Specifically for cancer vaccines, there are some further barriers. First is the characterization
of vaccines potency and toxicity. This is especially important in the transition from phase 2
to phase 3 trials. To select a meaningful and validated end point for trials is a big challenge
most of the time. Second barrier is selection of the maximum tolerated dose of cancer vac‐
cine, particularly compared with traditional anticancer agents. Cancer vaccines are typically
not very toxic. So the optimum dose often has to be based on the immune response of pa‐
tients. But if the patients have previously been heavily treated with other anticancer agents,
this can lead to a compromised immune system that makes it difficult to detect an evoked
immune response. The third barrier is appropriate trial design and statistical data process.
This is also a key part and can substantially affect final trial outcome [53].
6. Future directions
With the rapidly rising incidence and the high resistance to current therapeutic agents, de‐
veloping more effective drugs for metastatic melanoma is urgently needed. But before we
can thoroughly understand all the major molecular pathological changes associated with
melanoma malignancy, it is very difficult to reach a cure for it.
Melanoma is an extremely complicated disease, with many gene mutation and signaling
pathway changes. Elevated signaling pathway in melanoma including mitogen-activated
protein kinase (MAPK) pathway, phosphatidylinositol 3 kinase (PI3K)-AKT pathway, Wnt-
Frizzled-β-catenin pathway, JAK/Stat pathway and α-MSH-MC1R or microphthalmia-asso‐
ciated transcription factor (MITF) pathway. The first two are crucial pathway accounting for
melanoma malignance. Gene mutation that are involved in melanoma include the following
oncogenes: BRAF, N-ras, akt3; tumor suppressors: CDKN2A, PTEN, p53, APAF-1, p16, p15,
p19; others: Cyclin D1, MITF etc [81].
The binding of growth factors to their respective receptors leads to activation of RAS pro‐
teins. Ras will then activate Raf. Raf activate mitogen-activated protein kinase (MEK), which
then act on extracellular-related kinase (ERK). Phosporylated ERK kinases (ERK-P) translo‐
cate to the nucleus and activate transcription factors, which promote cell cycle progression
and proliferation. The PI3K-AKT pathway mediates cell survival signaling via growth fac‐
tors. Phosphatase and tensin homolog (PTEN) inhibits growth factor signaling by inactivat‐
ing phosphatidylinositol triphosphate (PIP3) generated by PI3K. Activated PI3K converts
the plasma membrane lipid phosphatidylinositol 4,5-bisphosphonate to PIP3, which acts as
a second messenger leading to the phosphorylation AKT and subsequent up-regulation of
cell cycle, growth, and survival proteins. AKT can also up-regulate mTOR (mammalian tar‐
get of rapamycin), S6K, and NFκb leading to cell growth and inhibition of apoptosis.
Knowing the huge complexity of melanoma, it’s easy to understand why so many random
trials of single agents or combinational treatment have failed. So targeted therapy in a sys‐
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temic way based on the understanding about melanoma molecular pathology seems to be a
reasonable way to fight this disease.
Individualized T-cell-based therapy is a very promising approach. Combined with other
suitable tumor killing agents, it could improve the patient survival rate and time. Unfortu‐
nately, the selective tumor-reactive T-cells isolated from a patient can only be used for this
same patient. Thus the cost associated with this treatment method is very high. Such an ex‐
pensive treatment may not be available to all the patients in the near future.
In learning from our efforts in the past, we must continue to challenge the current para‐
digms of treatment as we forge new paths to more effective treatment options. This will like‐
ly involve a multimodal approach to therapy utilizing all of the available tools in our
arsenal. Several agents given in unique combinations may then synergize with standard che‐
motherapeutic regimens resulting in prolonged clinical responses and long term survival.
Take Sorafenib as an example, its failure maybe largely due to the fact that it only blocks the
RAF-MEK-ERK signaling pathway. Melanoma cells can still survive by compensatory up-
regulation in other survival pathways such as the PI3K-AKT pathway. Melanoma can also
develop drug resistance with time by over-expressing MDR genes. Ideally, if we can use
drugs to synergistically block all the major survival pathways in melanoma cells and then
educate our immune system to fight the tumor cells, we will have a much better chance to
conquer this deadly disease.
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